...
首页> 外文期刊>Andrologia >Morphological reseach on expression of inflammatory mediators in murine models of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) induced by T2 antigen
【24h】

Morphological reseach on expression of inflammatory mediators in murine models of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) induced by T2 antigen

机译:T2抗原诱导慢性前列腺炎慢性前列腺炎鼠模型炎症介质表达的形态学研究

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common clinical syndrome with unknown aetiology. In this study, we used the T2 peptide in C57BL/6 (B6) mice and Sprague Dawley (SD) rats model during different stages. We sought to understand the role of CD4 + T cells and macrophages in CP/CPPS. A total of 16 B6 mice and 18 SD rats were divided into five groups: B6‐na?ve ( n ?=?6), B6 model ( n ?=?10), SD‐na?ve ( n ?=?6), SD‐45‐day model ( n ?=?6) and SD‐56‐day model ( n ?=?6). The B6 model group was subcutaneously injected with 0.2?ml of (225μg/ml) T2 peptide on 0 and 14th day and was finally sacrificed on 28th day. The SD‐45‐ and SD‐56‐day model groups were subcutaneously injected with 1ml of (50?μg/ml) T2 peptide on 0 and 14th day and were finally sacrificed on 45th and 56th day respectively. An equivalent volume of normal saline (NS) solution was injected to the na?ve groups and analysed the pain and voiding behaviour. We have calculated the prostate index, H&E staining and immunofluorescence of CD4 + T cells and macrophages (CD68) in each group. T2 peptide immunization in B6 mice and SD rats caused severe prostatitis and cell infiltration, mainly composed of CD4 + T cells and macrophages. The SD‐56‐day model group showed more severe inflammatory cells infiltration than SD‐45‐day model group. Moreover, inflammatory cells infiltration and red secretions in B6 model were less than SD model. Expression of CD4 + T cells and macrophages was also consistent with H&E results. These results indicated that different stages of CP/CPPS, inflammatory response, and the inflammation of the rat were stronger than the mouse. Our study suggests that CD4 + T cells and macrophages are key factors in the development of CP/CPPS.
机译:摘要慢性前列腺炎/慢性盆腔疼痛综合征(CP / CPP)是一种常见的临床综合征,具有未知的病态。在该研究中,我们在不同阶段使用C57BL / 6(B6)小鼠中的T2肽和Sprague Dawley(SD)大鼠模型。我们试图了解CD4 + T细胞和巨噬细胞在CP / CPP中的作用。总共16只B6小鼠和18只SD大鼠分为五组:B6-Na?ve(n?=?6),B6模型(n?=?10),sd-na?ve(n?=?6 ),SD-45天模型(n?=?6)和SD-56天模型(n?=?6)。将B6型号组皮下注射0.2?ml(225μg/ ml)T2肽0和14天,最后在第28天处死。将SD-45-和SD-56天模型基团皮下注射在0和14天的1ml(50μg/ ml)T2肽,并最终分别在第45和第56天处死。将相当体积的正常盐水(NS)溶液注入Na'Ve组并分析疼痛和排尿行为。我们已经计算了前列腺指数,H& CD4 + T细胞的染色和免疫荧光和每组的巨噬细胞(CD68)。 T2肽免疫在B6小鼠和SD大鼠中引起严重的前列腺炎和细胞浸润,主要由CD4 + T细胞和巨噬细胞组成。 SD-56日模型组显示比SD-45天模型组更严重的炎症细胞浸润。此外,B6模型中的炎症细胞浸润和红色分泌物小于SD模型。 CD4 + T细胞和巨噬细胞的表达也与H& E结果一致。这些结果表明,不同阶段的CP / CPP,炎症反应和大鼠的炎症比小鼠更强。我们的研究表明,CD4 + T细胞和巨噬细胞是CP / CPPS发展的关键因素。

著录项

  • 来源
    《Andrologia》 |2019年第11期|共9页
  • 作者单位

    Department of Clinical PharmacyChina Pharmaceutical University School of PharmacyNanjing China;

    School of PharmacyNanjing Medical UniversityNanjing China;

    School of Public HealthNanjing Medical UniversityNanjing China;

    Department of Clinical PharmacyChina Pharmaceutical University School of PharmacyNanjing China;

    Department of Clinical PharmacyChina Pharmaceutical University School of PharmacyNanjing China;

    Department of Clinical PharmacyChina Pharmaceutical University School of PharmacyNanjing China;

    School of Basic Medical SciencesNanjing Medical UniversityNanjing China;

    Department of Clinical PharmacyChina Pharmaceutical University School of PharmacyNanjing China;

    School of PharmacyNanjing Medical UniversityNanjing China;

    Department of Clinical PharmacyChina Pharmaceutical University School of PharmacyNanjing China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 男性生殖器疾病;
  • 关键词

    CD4 + T cells; CP/CPPS; EAP; macrophages; T2 peptide;

    机译:CD4 + T细胞;CP / CPPS;EAP;巨噬细胞;T2肽;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号